Phase I - Escalating Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Locally Advanced Adenocarcinoma of the Pancreas, and a Single Dose Study of siG12D LODER (Local Drug EluteR) in Patients With Non-operable Adenocarcinoma of the Pancreas

计划入组 15 人 · 首次发布于 2010 年 8 月 25 日

A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer

计划入组 80 人 · 首次发布于 2012 年 8 月 30 日

Lower Limb Resistance Training in Older Inpatients

计划入组 60 人 · 首次发布于 2014 年 5 月 19 日

siG13D-LODER

siG12D LODER

KRASG12D-LODER

Klinikum Frankfurt (Oder) GmbH

Germany

The Lower Valley Hospital Association

United States

Silexion's LODER Shows Promise in Non-Resectable Pancreatic Cancer

SIL-204 Demonstrates Synergy with Chemotherapy in KRAS-Driven Pancreatic Cancer Models

Silexion Therapeutics Receives Israeli Regulatory Approval for Phase 2/3 Trial of KRAS-Targeting RNAi Therapy SIL204